This week's BIO CEO conference is the largest conference of publicly traded biotech companies, and in this video, Motley Fool health care bureau chief Brenton Flynn highlights some takeaways from the conference. He discusses Celgene (CELG) CEO Bob Hugin's fireside chat at the beginning of the conference, where he told investors about the company's FDA approval for its relapsed/refractory multiple myeloma drug Pomalyst. Hugin also discussed why he doesn't see Onyx's (NASDAQ: ONXX) drug Krypolis to be a direct competitor, and how Celgene intends to maximize the opportunity it has with its top-selling drug, Revlimid.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Celgene's CEO Talks New Approvals, Future Opportunities
NASDAQ: CELG
Celgene

Important stories from the biggest conference in biotech investing.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.